Oregon Health and Science University
ohsu.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
686
Active
132
Phase 3
14
Total enrollment
6,762,897
Pipeline matrix
Showing 40 of 44 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ulipristal acetate | — | — | — | — | — | 2 | |
| Sevoflurane | — | — | — | — | — | 2 | |
| Propofol | — | — | — | — | 2 | ||
| Extended oral tranexamic acid regimen | — | — | — | — | — | 1 | |
| Aficamten | — | — | — | — | — | 1 | |
| Chlorhexidine | — | — | — | — | — | 1 | |
| Sterile Water | — | — | — | — | — | 1 | |
| Prednisone 20 Mg | — | — | — | — | — | 1 | |
| Norethindrone 0.35 MG | — | — | — | — | — | 1 | |
| Drospirenone | — | — | — | — | — | 1 | |
| Hypertonic saline | — | — | — | — | — | 1 | |
| Azithromycin | — | — | — | — | — | 1 | |
| Ethambutol | — | — | — | — | — | 1 | |
| Rifampin | — | — | — | — | — | 1 | |
| Abdominal wall injections with lidocaine 2% | — | — | — | — | — | 1 | |
| Iron-Dextran Complex Injection [InFed] | — | — | — | — | — | 1 | |
| Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months. | — | — | — | — | — | 1 | |
| Gonadotropin Releasing Hormone Antagonists Relugolix | — | — | — | — | — | 1 | |
| Hepatitis A vaccine | — | — | — | — | — | 1 | |
| Diphtheria, pertussis, and tetanus booster vaccine | — | — | — | — | — | 1 | |
| Amiodarone Hydrochloride | — | — | — | — | — | 1 | |
| Guselkumab | — | — | — | — | — | 2 | |
| Finerenone | — | — | — | — | — | 1 | |
| Sotagliflozin | — | — | — | — | — | 1 | |
| Cefotetan | — | — | — | — | — | 1 | |
| Carbapenems | — | — | — | — | — | 1 | |
| Beta Lactam Antibiotics | — | — | — | — | — | 1 | |
| 17D | — | — | — | — | — | 1 | |
| Clofazimine | — | — | — | — | — | 1 | |
| L-fucose | — | — | — | — | — | 1 | |
| Centella asiatica product | — | — | — | — | — | 1 | |
| Psilocybin | — | — | — | — | — | 1 | |
| Intramuscular administration of autologous BM-MNCs | — | — | — | — | — | 1 | |
| DMPA | — | — | — | — | — | 1 | |
| Etonogestrel implant | — | — | — | — | — | 1 | |
| Ferric derisomaltose | — | — | — | — | — | 1 | |
| OCT-guided laser phototherapeutic keratectomy | — | — | — | — | — | 1 | |
| Levonorgestrel Intrauterine System | — | — | — | — | — | 1 | |
| Norethindrone Acetate | — | — | — | — | — | 1 | |
| Positron Emission Tomography (PET) scanning of cardiac function at 3 time points across the 24 hour circadian cycle | — | — | — | — | — | 1 |
4 more active programs hidden
Next readouts
- 2024-09-30
- 2025-04-01
- 2025-08-29
- 2025-11-01
- 2025-11-30
- 2025-12
- 2025-12
- 2025-12-31
- 2025-12-31
- 2025-12-31
Top conditions
- Parkinson's Disease23
- Obesity22
- Multiple Sclerosis20
- Contraception18
- Pain15
- Type 1 Diabetes12
- Parkinson Disease11
- Depression11
Frequently asked questions about Oregon Health and Science University
- How many clinical trials does Oregon Health and Science University have on ClinicalTrials.gov?
- Oregon Health and Science University is listed as the lead sponsor on 686 clinical trials in ClinicalTrials.gov, 132 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Oregon Health and Science University's trials are in Phase 3?
- 14 of Oregon Health and Science University's trials are in Phase 3, spread across 44 active drug programs.
- What therapeutic areas does Oregon Health and Science University focus on?
- Oregon Health and Science University's most-studied conditions on ClinicalTrials.gov are Parkinson's Disease, Obesity, Multiple Sclerosis, Contraception, Pain.
- When are Oregon Health and Science University's next clinical trial readouts?
- Oregon Health and Science University has 10 upcoming primary-completion readouts tracked here; the soonest is “Body Weight, Sleep, and Heart Health”, expected around 2024-09-30.